Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

Summary

This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.

Timeline

Start

2025-07-08

Primary completion

2027-05

Completion

2030-06

Drugs

Indications